AbbVie Inc. (ABBV) Tax Rate: 35.83%
Is AbbVie Inc.’s tax rate high or low?
AbbVie Inc.'s tax rate of 35.83% is 624% above its 5-year average of 4.95%, near the high end of its 5-year range (-36.02%–35.83%).
The tax rate for AbbVie Inc. (ABBV) is 35.83%. It is above its 12-month average by 249.73% (10.24%).
ABBV Tax Rate Chart
ABBV Average Tax Rate Chart
ABBV Current vs Average Tax Rate Chart
ABBV Tax Rate Metrics
TAX RATE
35.83%
TAX RATE AVG TTM
10.24%
TAX RATE AVG 3Y
13.66%
TAX RATE AVG 5Y
4.95%
TAX RATE AVG 10Y
9.55%
TAX RATE AVG 15Y
11.29%
TAX RATE AVG 20Y
11.93%
CURRENT VS TTM AVG
+249.73%
CURRENT VS 3Y AVG
+162.35%
CURRENT VS 5Y AVG
+623.84%
CURRENT VS 10Y AVG
+275.00%
CURRENT VS 15Y AVG
+217.29%
CURRENT VS 20Y AVG
+200.41%
AbbVie Inc. Tax Rate Formula & Definition
Tax rate measures income tax expense as a percentage of income before tax. It helps compare tax efficiency and identify unusual tax effects.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AbbVie Inc. Tax Rate FAQ
- What is the tax rate for AbbVie Inc. (ABBV)?
- The tax rate for ABBV stock is 35.83%.
- Is AbbVie Inc.'s tax rate high or low?
- AbbVie Inc.'s tax rate of 35.83% is 624% above its 5-year average of 4.95%, near the high end of its 5-year range (-36.02%–35.83%).
- What is the TTM average tax rate for AbbVie Inc. (ABBV)?
- The TTM average tax rate for ABBV stock is 10.24%.
- What is the 3Y average tax rate for AbbVie Inc. (ABBV)?
- The 3Y average tax rate for ABBV stock is 13.66%.
- What is the 5Y average tax rate for AbbVie Inc. (ABBV)?
- The 5Y average tax rate for ABBV stock is 4.95%.
- What is the 10Y average tax rate for AbbVie Inc. (ABBV)?
- The 10Y average tax rate for ABBV stock is 9.55%.
- What is the 15Y average tax rate for AbbVie Inc. (ABBV)?
- The 15Y average tax rate for ABBV stock is 11.29%.
- What is the 20Y average tax rate for AbbVie Inc. (ABBV)?
- The 20Y average tax rate for ABBV stock is 11.93%.
AbbVie Inc. Tax Rate History
| DATE | TAX RATE |
|---|---|
| 2025-12-31 | 35.83% |
| 2024-12-31 | -15.34% |
| 2023-12-31 | 22.03% |
| 2022-12-31 | 12.11% |
| 2021-12-31 | 11.09% |
| 2020-12-31 | -36.02% |
| 2019-12-31 | 6.46% |
| 2018-12-31 | -9.43% |
| 2017-12-31 | 31.29% |
| 2016-12-31 | 24.49% |
| 2015-12-31 | 22.59% |
| 2014-12-31 | 25.12% |
| 2013-12-31 | 22.58% |
| 2012-12-31 | 7.86% |
| 2011-12-31 | 6.41% |
| 2010-12-31 | 13.61% |
| 2009-12-31 | 22.08% |
Related Metrics
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael